Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort

Table 5 Correlates of malignancy diagnosed within 5 years of systemic sclerosis onset^a, determined using logistic regression^b

Variable ^c	Odds ratio	95% confidence interval	P value
Anti-RNA polymerase III antibodies	4.2	1.3 to 13.4	0.01
Age of onset of systemic sclerosis	1.10	1.05 to 1.16	0.0002
Smoker			NS
Immunosuppressives			NS
Diffuse subtype			NS

NS, not significant. ^aBefore or after the onset of systemic sclerosis skin disease. ^bExcluding nonmelanoma skin cancers and the 'other' category. ^cEver from disease onset to most recent visit.

ISSN: 1478-6362